OptimizeRx Co. (NASDAQ:OPRX) CFO Douglas P. Baker sold 3,768 shares of the stock in a transaction dated Tuesday, September 14th. The stock was sold at an average price of $65.57, for a total value of $247,067.76. Following the sale, the chief financial officer now directly owns 44,796 shares in the company, valued at approximately $2,937,273.72. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Douglas P. Baker also recently made the following trade(s):
- On Wednesday, September 8th, Douglas P. Baker sold 10,000 shares of OptimizeRx stock. The stock was sold at an average price of $67.25, for a total value of $672,500.00.
- On Tuesday, August 24th, Douglas P. Baker sold 4,000 shares of OptimizeRx stock. The stock was sold at an average price of $61.50, for a total value of $246,000.00.
- On Monday, June 28th, Douglas P. Baker sold 3,421 shares of OptimizeRx stock. The shares were sold at an average price of $63.00, for a total value of $215,523.00.
Shares of NASDAQ OPRX opened at $69.51 on Friday. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of 579.25 and a beta of 0.66. OptimizeRx Co. has a 1-year low of $17.01 and a 1-year high of $73.88. The stock’s 50-day moving average is $60.73 and its 200 day moving average is $54.27.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in shares of OptimizeRx by 2.3% during the 2nd quarter. BlackRock Inc. now owns 1,104,157 shares of the company’s stock valued at $68,347,000 after buying an additional 25,268 shares in the last quarter. Vanguard Group Inc. grew its position in OptimizeRx by 12.5% during the 2nd quarter. Vanguard Group Inc. now owns 774,349 shares of the company’s stock worth $47,932,000 after acquiring an additional 86,181 shares during the last quarter. Artisan Partners Limited Partnership bought a new position in OptimizeRx during the 1st quarter worth approximately $37,653,000. Blair William & Co. IL grew its position in OptimizeRx by 0.4% during the 2nd quarter. Blair William & Co. IL now owns 755,074 shares of the company’s stock worth $46,739,000 after acquiring an additional 2,971 shares during the last quarter. Finally, First Light Asset Management LLC grew its position in OptimizeRx by 11.9% during the 2nd quarter. First Light Asset Management LLC now owns 664,842 shares of the company’s stock worth $41,154,000 after acquiring an additional 70,643 shares during the last quarter. 67.39% of the stock is currently owned by institutional investors.
Several analysts have weighed in on the company. B. Riley raised their price target on OptimizeRx from $80.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, August 5th. Zacks Investment Research cut OptimizeRx from a “buy” rating to a “hold” rating in a report on Thursday, July 8th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $70.80.
OptimizeRx Corp. is digital health company, which engages in the provision of digital health messaging via electronic health records, which serves as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging; and brand support.
Read More: Liquidity
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.